JPWO2022140587A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022140587A5 JPWO2022140587A5 JP2023537946A JP2023537946A JPWO2022140587A5 JP WO2022140587 A5 JPWO2022140587 A5 JP WO2022140587A5 JP 2023537946 A JP2023537946 A JP 2023537946A JP 2023537946 A JP2023537946 A JP 2023537946A JP WO2022140587 A5 JPWO2022140587 A5 JP WO2022140587A5
- Authority
- JP
- Japan
- Prior art keywords
- chr16
- cell
- engineered cell
- engineered
- ciita
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130098P | 2020-12-23 | 2020-12-23 | |
| US63/130,098 | 2020-12-23 | ||
| US202163251002P | 2021-09-30 | 2021-09-30 | |
| US63/251,002 | 2021-09-30 | ||
| US202163254971P | 2021-10-12 | 2021-10-12 | |
| US63/254,971 | 2021-10-12 | ||
| US202163288502P | 2021-12-10 | 2021-12-10 | |
| US63/288,502 | 2021-12-10 | ||
| PCT/US2021/064933 WO2022140587A1 (en) | 2020-12-23 | 2021-12-22 | Compositions and methods for genetically modifying ciita in a cell |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501246A JP2024501246A (ja) | 2024-01-11 |
| JP2024501246A5 JP2024501246A5 (https=) | 2025-09-02 |
| JPWO2022140587A5 true JPWO2022140587A5 (https=) | 2025-09-02 |
Family
ID=80445732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537946A Pending JP2024501246A (ja) | 2020-12-23 | 2021-12-22 | 細胞中のｃｉｉｔａを遺伝子修飾するための組成物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240139323A1 (https=) |
| EP (1) | EP4267723A1 (https=) |
| JP (1) | JP2024501246A (https=) |
| KR (1) | KR20230135068A (https=) |
| AU (1) | AU2021410751A1 (https=) |
| BR (1) | BR112023012432A2 (https=) |
| CA (1) | CA3205042A1 (https=) |
| CL (2) | CL2023001855A1 (https=) |
| CO (1) | CO2023009613A2 (https=) |
| CR (1) | CR20230321A (https=) |
| IL (1) | IL303970A (https=) |
| MX (1) | MX2023007465A (https=) |
| TW (1) | TW202242101A (https=) |
| WO (1) | WO2022140587A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116042676A (zh) * | 2023-01-04 | 2023-05-02 | 上海南方模式生物科技股份有限公司 | 一种基于CRISPR-Cas9构建TNF-α-HiBit动物模型的方法 |
| AU2024324870A1 (en) | 2023-08-14 | 2026-02-12 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| TW202521564A (zh) | 2023-08-14 | 2025-06-01 | 美商英特利亞醫療公司 | 用於基於細胞之療法的ｃｄ７０ ｃａｒ－ｔ組合物及方法 |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025049631A1 (en) * | 2023-08-28 | 2025-03-06 | Kyverna Therapeutics, Inc. | Allogeneic car-t cell therapies and manufacture thereof |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| KR940703846A (ko) | 1991-12-24 | 1994-12-12 | 비. 린네 파샬 | 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides) |
| US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
| WO2011091324A2 (en) | 2010-01-22 | 2011-07-28 | The Scripps Research Institute | Methods of generating zinc finger nucleases having altered activity |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| CA2895155C (en) | 2012-12-17 | 2021-07-06 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
| CN105683376A (zh) * | 2013-05-15 | 2016-06-15 | 桑格摩生物科学股份有限公司 | 用于治疗遗传病状的方法和组合物 |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| EP3265559B1 (en) | 2015-03-03 | 2021-01-06 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
| EA201891338A1 (ru) * | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
| TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| AU2017374044B2 (en) | 2016-12-08 | 2023-11-30 | Intellia Therapeutics, Inc. | Modified guide RNAs |
| EP4029943A1 (en) | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| MX2019013514A (es) * | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| PT3688162T (pt) | 2017-09-29 | 2024-04-23 | Intellia Therapeutics Inc | Formulações |
| WO2019118516A1 (en) * | 2017-12-11 | 2019-06-20 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| US11447769B2 (en) | 2018-03-27 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| WO2019237069A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Modified guide rnas for gene editing |
| WO2019237035A1 (en) * | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| BR112021007123A2 (pt) | 2018-10-15 | 2021-08-10 | University Of Massachusetts | edição de base de dna programável pelas proteínas de fusão nme2cas9-desaminase |
| JP2022512703A (ja) | 2018-10-16 | 2022-02-07 | インテリア セラピューティクス，インコーポレイテッド | 免疫療法のための組成物および方法 |
| WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
| KR20210128440A (ko) * | 2019-02-15 | 2021-10-26 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 범용 공여자 줄기 세포 및 관련 방법 |
| AU2020291457B2 (en) * | 2019-06-12 | 2024-11-14 | The Regents Of The University Of California | Engineered off-the-shelf immune cells and methods of use thereof |
| CN114457034A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-1阻断物的多能干细胞衍生物及其应用 |
-
2021
- 2021-12-22 TW TW110148207A patent/TW202242101A/zh unknown
- 2021-12-22 EP EP21854910.3A patent/EP4267723A1/en active Pending
- 2021-12-22 MX MX2023007465A patent/MX2023007465A/es unknown
- 2021-12-22 AU AU2021410751A patent/AU2021410751A1/en active Pending
- 2021-12-22 WO PCT/US2021/064933 patent/WO2022140587A1/en not_active Ceased
- 2021-12-22 CR CR20230321A patent/CR20230321A/es unknown
- 2021-12-22 JP JP2023537946A patent/JP2024501246A/ja active Pending
- 2021-12-22 CA CA3205042A patent/CA3205042A1/en active Pending
- 2021-12-22 IL IL303970A patent/IL303970A/en unknown
- 2021-12-22 KR KR1020237024498A patent/KR20230135068A/ko active Pending
- 2021-12-22 BR BR112023012432A patent/BR112023012432A2/pt unknown
-
2023
- 2023-06-20 CL CL2023001855A patent/CL2023001855A1/es unknown
- 2023-06-22 US US18/339,930 patent/US20240139323A1/en active Pending
- 2023-07-19 CO CONC2023/0009613A patent/CO2023009613A2/es unknown
- 2023-10-17 CL CL2023003089A patent/CL2023003089A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102749200B1 (ko) | 고콜레스테롤혈증 및 관련 상태를 치료하기 위한 pcsk9 표적화 올리고뉴클레오티드 | |
| US12270044B2 (en) | CRISPR systems with engineered dual guide nucleic acids | |
| TWI784934B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| CN108350454B (zh) | 等位基因选择性基因编辑及其用途 | |
| JP2024038326A5 (https=) | ||
| US9157081B2 (en) | Chimeric oligomeric compounds for modulation of splicing | |
| JP2021518160A5 (https=) | ||
| JP2022524212A (ja) | 操作されたｍＲＮＡ配列及びその使用 | |
| WO2018067991A1 (en) | Modulation of novel immune checkpoint targets | |
| JP2018510219A (ja) | Ｔａｔ誘導性ｃｒｉｓｐｒ／エンドヌクレアーゼに基づく遺伝子編集 | |
| EP3368689A2 (en) | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures | |
| WO2017075451A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 | |
| US20250144149A1 (en) | Adenosine deaminase base editors and methods for use thereof | |
| JPWO2019178426A5 (https=) | ||
| JPWO2022140587A5 (https=) | ||
| US20230114151A1 (en) | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression | |
| JPWO2018164275A1 (ja) | アンチセンスオリゴヌクレオチドおよび糖原病Ｉａ型予防または治療用組成物 | |
| WO2022248879A1 (en) | Composition and method for adar-mediated rna editing | |
| EP0811071B1 (fr) | Sequences amplificatrices derivees du gene de la desmine, vecteurs portant ces sequences et leurs utilisations pour la production de proteines | |
| JPWO2022256440A5 (https=) | ||
| KR20200127211A (ko) | Gys2 발현을 억제하기 위한 조성물 및 방법 | |
| TW202425952A (zh) | 脂質奈米顆粒藥物綴合物 | |
| CN118043461A (zh) | 方法 | |
| JPWO2022140586A5 (https=) | ||
| CA3147641A1 (en) | Compositions and methods for modulating apolipoprotein b (apob) gene expression |